2235393-30-1

2235393-30-1 structure

Name: Anticancer agent 164
Chemical Name: Anticancer agent 164
CAS Number: 2235393-30-1
Molecular Formula: C₂₁H₂₃F₃N₈O₂S₂
Molecular Weight: 540.58
Catalog: Signaling Pathways Apoptosis Apoptosis
Create Date: 2024-01-26 18:34:13
Modify Date: 2024-01-26 18:34:13
CML-IN-1 (compound 7) is a potent anticancer agent. CML-IN-1 displays very good induced-apoptosis effect for human chronic myeloid leukemia (CML) cell line K562. CML-IN-1 exerts its effect via a significantly reduced protein phosphorylation of PI3K/Akt signal pathway. CML-IN-1 (compound 4) also inhibits cell proliferation by suppressing the MEK/ERK signaling pathway in colorectal cancer[1][2].

Name	Anticancer agent 164

Description	CML-IN-1 (compound 7) is a potent anticancer agent. CML-IN-1 displays very good induced-apoptosis effect for human chronic myeloid leukemia (CML) cell line K562. CML-IN-1 exerts its effect via a significantly reduced protein phosphorylation of PI3K/Akt signal pathway. CML-IN-1 (compound 4) also inhibits cell proliferation by suppressing the MEK/ERK signaling pathway in colorectal cancer[1][2].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer Signaling Pathways >> MAPK/ERK Pathway >> MEK Signaling Pathways >> PI3K/Akt/mTOR >> PI3K
References	[1]. Li W, et al. Design and synthesis of novel 1-phenyl-3-(5-(pyrimidin-4-ylthio)-1,3,4-thiadiazol- 2-yl)urea derivatives with potent anti-CML activity throughout PI3K/AKT signaling pathway. Bioorg Med Chem Lett. 2019 Jul 15;29(14):1831-1835. [2]. Li W, et al. A novel 4-(1,3,4-thiadiazole-2-ylthio)pyrimidine derivative inhibits cell proliferation by suppressing the MEK/ERK signaling pathway in colorectal cancer. Acta Pharm. 2023 Sep 14;73(3):489-502.

Molecular Formula	C₂₁H₂₃F₃N₈O₂S₂
Molecular Weight	540.58